“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
ACADEMIA
Japan Plans Alvesco Clinical Trial for Coronavirus
Japan’s National Center for Global Health and Medicine (NCGM) is planning a clinical trial for Teijin’s Alvesco (ciclesonide), an inhaled corticosteroid for asthma, for the treatment of pre-symptomatic patients infected with the novel coronavirus. The trial will examine whether Alvesco…
To read the full story
Related Article
- Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
December 24, 2020
- 26 Patients Enrolled in Alvesco’s Novel Coronavirus Trial: NCGM
June 1, 2020
- Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
May 11, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- Japan Can’t Give “Special Approval” for Avigan under Current Law: Abe
April 30, 2020
- Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
- Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
- Japan’s Avigan Stockpile for Some 2 Million People; No Plan for Increase: Govt
March 18, 2020
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
- Japan Govt Orders 20,000 Alvesco Inhalers as Coronavirus Measure
March 11, 2020
- Camostat Potential Treatment for COVID-19: German Study
March 11, 2020
- Alvesco Inhibits RNA Replications: NIID
March 9, 2020
- With Sudden Spotlight on Alvesco for COVID-19, Teijin Being Flooded with Inquiries
March 6, 2020
- Asthma Drug Alvesco Possibly Effective for COVID-19
March 4, 2020
ACADEMIA
- Over Half of Pregnant Women Shun COVID Jab for Side Effect Fears: Survey
December 6, 2022
- Lewy Body Dementia Specialist Sees Aricept Approval Modification as Positive Move
December 6, 2022
- Building Delivery Scheme for Disease-Modifying Drugs for Alzheimer’s Is Critical: Academic Societies
November 30, 2022
- Obesity Society to Highlight Proper Use of Semaglutide If Label Expanded
November 29, 2022
- Japan Infectious Diseases Association Updates Guidelines after Xocova Approval
November 25, 2022
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…